Liposomal‐encapsulated doxorubicin supercharge‐containing front‐line treatment improves response rates in primary mediastinal large B‐cell lymphoma and mediastinal gray zone lymphoma.

This article explores the use of a new treatment regimen, R-COMP-DIx6, in the treatment of primary mediastinal large B-cell lymphoma (PMBL) and mediastinal gray zone lymphoma (MGZL). The study found that the regimen, which includes an increased dose of liposomal-encapsulated doxorubicin (Myocet™), resulted in a high rate of complete metabolic response and favorable progression-free survival rate in patients. The study also examined the impact of tumor-infiltrating macrophages on treatment outcomes. However, the study had a small sample size and further research is needed to determine the effectiveness of this treatment in a larger clinical trial. [Extracted from the article]